CN115349498A - Construction method of damp-heat type endometritis mouse model - Google Patents
Construction method of damp-heat type endometritis mouse model Download PDFInfo
- Publication number
- CN115349498A CN115349498A CN202211113443.2A CN202211113443A CN115349498A CN 115349498 A CN115349498 A CN 115349498A CN 202211113443 A CN202211113443 A CN 202211113443A CN 115349498 A CN115349498 A CN 115349498A
- Authority
- CN
- China
- Prior art keywords
- damp
- model
- heat
- mouse
- endometritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004145 Endometritis Diseases 0.000 title claims abstract description 51
- 238000010276 construction Methods 0.000 title claims abstract description 23
- 238000010172 mouse model Methods 0.000 title claims abstract description 23
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 34
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 33
- 241000699670 Mus sp. Species 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 235000019198 oils Nutrition 0.000 claims description 9
- 210000000683 abdominal cavity Anatomy 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 239000002504 physiological saline solution Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 210000002969 egg yolk Anatomy 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 abstract description 22
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 11
- 238000010171 animal model Methods 0.000 abstract description 8
- 230000007246 mechanism Effects 0.000 abstract description 3
- 210000001215 vagina Anatomy 0.000 abstract description 2
- 230000014509 gene expression Effects 0.000 description 18
- 102000004363 Aquaporin 3 Human genes 0.000 description 12
- 108090000991 Aquaporin 3 Proteins 0.000 description 12
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 12
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 108090000174 Interleukin-10 Proteins 0.000 description 8
- 210000004291 uterus Anatomy 0.000 description 8
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- CAOOISJXWZMLBN-PPHPATTJSA-N htn0d03vrz Chemical compound Cl.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 CAOOISJXWZMLBN-PPHPATTJSA-N 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 102000010637 Aquaporins Human genes 0.000 description 3
- 108010063290 Aquaporins Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000030373 chronic endometritis Diseases 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000722713 Carcharodon carcharias Species 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 241001051118 Garcinia nigrolineata Species 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 241000087799 Koma Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000004171 acute endometritis Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/25—Animals on a special diet
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/35—Animals modified by environmental factors, e.g. temperature, O2
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a construction method of a damp-heat type endometritis mouse model, belonging to the technical field of animal model construction; in the method, a high-fat high-sugar feed is adopted to feed the mice in a damp-heat environment, and in the feeding process, oil feeding is performed in a single-day matched mode, and white spirit feeding is performed in a double-day matched mode, so that the damp-heat syndrome model mice are obtained; and (3) carrying out endometritis disease model modeling on the damp-heat syndrome model mouse to obtain a damp-heat type endometritis mouse model. The construction method of the invention fills the blank of the damp-heat type endometritis animal model. Therefore, the experiment is used for modeling a damp-heat syndrome model and a disease model, and provides reliable technical support for researching a mechanism for treating damp-heat type endometritis. The construction method of the invention is divided into damp-heat syndrome model modeling and disease model modeling, wherein the operation modeling of the disease model has high success rate (99%) and stable model compared with the traditional vagina pouring Lipopolysaccharide (LPS).
Description
Technical Field
The invention belongs to the technical field of animal model construction, and particularly relates to a construction method of a damp-heat type endometritis mouse model.
Background
Endometritis is a gynecological disease characterized by inflammation of endometrial glands and interstitial tissues, which is divided into acute and chronic diseases, and can be singly attacked or accumulated in a plurality of parts. Due to the widespread use of antibiotics, acute endometritis is relatively rare. Chronic Endometritis (CE) is overlooked due to lack of specific clinical symptoms, and researches show that CE can cause a series of adverse effects such as female infertility risk increase, embryo implantation failure, abnormal uterine bleeding and the like.
The ancient books of traditional Chinese medicine have no record of endometritis, and belong to the morbid leucorrhea, bellyache of husband, heat entering blood room and the like of the traditional Chinese medicine according to the symptom characteristics of endometritis. TCM considers that the etiology is multiple and the pathogenesis is complex, but it can be summarized into 5 aspects of dampness, heat, stasis, cold and deficiency. Damp-heat is a main pathogenic factor of endometritis, and blood stasis blocking is the basic pathogenesis of the endometritis. Therefore, it is important to construct a damp-heat type endometritis model and to deeply explore the treatment mechanism.
However, there is no record on the construction of an animal model of damp-heat endometritis at present.
Disclosure of Invention
The invention aims to provide a construction method of a damp-heat type endometritis mouse model, which fills the blank of the damp-heat type endometritis animal model.
The invention provides a construction method of a damp-heat type endometritis mouse model, which comprises the following steps:
1) Feeding the mice with high-fat high-sugar feed in a damp-heat environment, wherein in the feeding process, oil feeding is performed in a single-day mode, and liquor feeding is performed in a double-day mode to obtain damp-heat syndrome model mice;
the raising period is 25-30 d;
the feeding time in a damp and hot environment is 8-10 h every day;
2) And (3) carrying out endometritis disease model modeling on the damp-heat syndrome model mouse to obtain a damp-heat type endometritis mouse model.
Preferably, the temperature of the damp and hot environment is 29.85-30.15 ℃; the humidity of the damp and hot environment is 80-90%.
Preferably, the high-fat high-sugar feed comprises the following components in percentage by mass: 55% basal feed, 12% palm oil, 18% sucrose, 3% cholesterol, 7% egg yolk powder and 5% protein powder.
Preferably, the alcohol content of the white spirit is 50-56 degrees.
Preferably, before the white spirit is fed, the white spirit is diluted by water, and the volume ratio of the water to the white spirit is (1-1.2) to 1; the feeding amount of the diluted white spirit is 0.5-0.8 ml/100g of mouse body weight.
Preferably, the feeding amount of the oil is 0.5-0.8 ml/100g of mouse body weight.
Preferably, the step of carrying out endometritis symptom model building on the damp-heat syndrome model mouse comprises the steps of sequentially anaesthetizing the damp-heat syndrome model mouse, injecting an LPS (lipopolysaccharide) aqueous solution into a uterine cavity and injecting physiological saline into an abdominal cavity; the concentration of the LPS in the LPS water solution is 2-2.5 mu g/mu l; the injection amount of the LPS aqueous solution is 20-25 mul/piece; the injection amount of the normal saline is 0.08-0.1 ml/10g of mouse body weight.
The invention provides a construction method of a damp-heat type endometritis mouse model, which comprises the steps of feeding a mouse by adopting high-fat high-sugar feed under a damp-heat environment, and feeding oil on a single day and white spirit on double days in a matching manner in the feeding process to obtain a damp-heat syndrome model mouse; and (3) carrying out endometritis disease model modeling on the damp-heat syndrome model mouse to obtain a damp-heat type endometritis mouse model.
Dampness pathogen, dampness pathogen is internal dampness and external dampness, the internal dampness is related to improper diet (fat, sweet, thick and greasy diet, insufficiency of spleen yang, inability to transport and transform water dampness, injury to collaterals) and the external dampness is related to humid environment of residence. Therefore, the construction method of the invention is that the mice are placed in a damp-heat environment and fed with high-fat and high-sugar feed, and the spleen and the stomach of the mice are promoted to be injured by adopting white spirit to jointly construct a damp-heat syndrome model; and then carrying out endometritis disease model modeling on the damp-heat syndrome model mouse to obtain a damp-heat type endometritis mouse model. The animal model of the traditional Chinese medicine standard should be divided into syndrome and disease models, and considering that the syndrome model is complicated in dialectical form, the model can be made by means which can not be understood by common people, and is difficult to succeed, and most of models are only made into disease models. Clinically, endometritis diagnosed by traditional Chinese medicine is mostly damp-heat type, but a molding method of damp-heat type endometritis does not exist in the prior art, and the construction method fills the blank of a damp-heat type endometritis animal model. The invention carries out model building of damp-heat syndrome model and disease model, and provides reliable technical support for exploring the mechanism for treating damp-heat type endometritis. The construction method of the invention is divided into damp-heat syndrome model modeling and disease model modeling, wherein the operation modeling of the disease model has high success rate (99%) and stable model compared with the traditional vagina pouring Lipopolysaccharide (LPS).
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed to be used in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without inventive exercise.
FIG. 1 is a view of the modeling of surgical conditions, injected with LPS in the uterine cavity;
FIG. 2 shows the general conditions of the mouse model for damp-heat, wherein A is the normal group and B is the damp-heat syndrome model group;
FIG. 3 shows the change of uterine morphology of mice in each group, wherein A is a blank group, B is a model group, and C is a treatment group;
FIG. 4 shows HE staining (200X) of uterus of mice in each group at a scale of 100 μm, wherein A is blank, B is model, and C is treatment;
FIG. 5 shows the expression of CD14 in endometrium (X200) of each group of mice, wherein A is blank group, B is model group, and C is treatment group;
FIG. 6 is a statistical analysis of the mean Optical Density (OD) of mouse endometrial CD14 compared to a blank model group ## P is less than 0.01, and the model group is compared with the treatment group ** P<0.01;
FIG. 7 shows the gastric AQP3 expression (x 200) of mice in each group, wherein A is a blank group, B is a model group, and C is a treatment group;
FIG. 8 is a statistical analysis of the mean optical density (OD values) of mouse gastric AQP3, wherein the model group is compared to the blank group ## P is less than 0.01, and the model group is compared with the treatment group ** P<0.05;
FIG. 9 is a graph showing the results of statistical analysis (pg/ml) of the expression of inflammatory factors in mice of each group, in which A is TNF-a, B is IL-10, and C is IL-8, compared with the blank group, the model group ## P is less than 0.01, and the model group is compared with the treatment group ** P<0.05;
FIG. 10 shows the results of HE staining of tongue tissues in each group (200X) where A is blank, B is model, and C is treatment.
Detailed Description
The invention provides a construction method of a damp-heat type endometritis mouse model, which comprises the following steps:
1) Feeding the mice with high-fat high-sugar feed in a damp-heat environment, wherein in the feeding process, oil feeding is performed in a single-day mode, and liquor feeding is performed in a double-day mode to obtain damp-heat syndrome model mice;
the feeding period is 25-30 d;
the feeding time in a damp and hot environment is 8-10 h every day;
2) And (3) carrying out endometritis disease model modeling on the damp-heat syndrome model mouse to obtain a damp-heat type endometritis mouse model.
Firstly, feeding a mouse by adopting high-fat high-sugar feed in a damp-heat environment, wherein in the feeding process, oil feeding is performed in a single-day mode, and liquor feeding is performed in a double-day mode to obtain a damp-heat syndrome model mouse; the feeding period is 25-30 d; the feeding time in the moist heat environment is 8-10 h per day, and the feeding time period in the moist heat environment is preferably 10-00.
In the invention, the temperature of the damp and hot environment is preferably 29.85-30.15 ℃, and more preferably 30 ℃; the humidity of the moist heat environment is preferably 80% to 90%, more preferably 85%.
In the invention, the degree of the white spirit is preferably 50-56 degrees; the white spirit is preferably 56-degree Hongxing Erguotou produced by Beijing Hongxing GmbH. In the invention, before the white spirit is fed, the white spirit is preferably diluted by water, and the volume ratio of the water to the white spirit is preferably (1-1.2) to 1; the feeding amount of the diluted white spirit is preferably 0.5-0.8 ml/100g of mouse body weight.
In the invention, the feeding amount of the oil is preferably 0.5-0.8 ml/100g of mouse body weight; the oil preferably includes vegetable oil and animal oil; the vegetable oil preferably comprises peanut oil.
After obtaining the damp-heat syndrome model mouse, the invention carries out endometritis disease model modeling on the damp-heat syndrome model mouse to obtain a damp-heat type endometritis mouse model.
The method for modeling the endometritis disease model is not particularly limited, and a conventional method for modeling the endometritis disease model in the field can be adopted.
In the invention, the model building of the endometritis symptom model of the damp-heat syndrome model mouse preferably comprises the steps of sequentially anaesthetizing the damp-heat syndrome model mouse, injecting LPS aqueous solution into uterine cavity and injecting physiological saline into abdominal cavity; the concentration of the LPS in the LPS water solution is preferably 2-2.5 mu g/mu l; the injection amount of the LPS aqueous solution is preferably 20-25 mu l/piece; the injection amount of the physiological saline is preferably 0.08 to 0.1ml/10g of mouse body weight.
In the present invention, the mode of anesthesia is preferably intraperitoneal injection of pentobarbital sodium, and the injection amount of the pentobarbital sodium is preferably 40-70 mg/kg of mouse body weight, and more preferably 50-60 mg/kg of mouse body weight.
Before the LPS aqueous solution is injected into the uterine cavity, the invention preferably also comprises skin preparation, disinfection, placement in the abdomen from the position of 0.4-0.5 cm below the kidney area at the back to see white ovarian tissues, finding out the uterus in a homeopathic manner, and the LPS aqueous solution is injected into the uterine cavity; the operation approach taken by the operation is a back operation path, so that the chance of contacting with intestinal tracts is avoided, the operation complications such as postoperative infection, intestinal flatulence, intestinal adhesion, intestinal obstruction and the like are reduced, the additional interference caused by the model building is reduced, and the success rate of the model building is ensured.
In the present invention, the intrauterine injection of the LPS aqueous solution is preferably performed using a microinjector.
After LPS aqueous solution is injected into the uterine cavity, the abdomen is closed according to the anatomical level, the sterilization is carried out, the normal saline is injected into the abdominal cavity preferentially, and the fluid infusion is carried out, so that the hypovolemia, hemorrhagic shock and death caused by fasting and operation are reduced.
After the normal saline is injected into the abdominal cavity, the preferred lateral decubitus position or prone position is placed into an artificial climate box for reviving, so that death caused by hypothermia due to anesthesia is reduced, and meanwhile, suffocation death caused by tongue root tenesmus and vomiting is avoided; the temperature in the climatic chamber is preferably 28 ℃. The invention simulates the postoperative management mode in clinical operation and ensures the success rate of model making.
The method of the invention is suitable for all animal surgery modeling.
For further illustration of the present invention, the following will describe the construction method of a mouse model of damp-heat endometritis in detail with reference to the drawings and examples, but they should not be construed as limiting the scope of the present invention.
Example 1
1. Laboratory animal
30 Kunming female mice with the SPF grade of 8-10 weeks have the average weight of 30-35 g, are purchased from Tianqin biotechnology limited company of Changsha city, and have the animal qualification number of 430726220100069835 and the production license number of SCXK (Xiang) 2019-0014.
2. Feed stuff
The high-fat high-sugar feed is processed by an animal experiment center of Guangxi Chinese medicinal university, and the formula comprises the following components in percentage by mass: 55% of basal feed, 12% of palm oil, 18% of sucrose, 3% of cholesterol, 7% of yolk powder and 5% of protein powder; the basic feed is provided by animal experiment center of Guangxi Chinese medicine university.
3. Test drugs
Levofloxacin hydrochloride tablets: zhejiang Jing New medicine industries, inc. (approved literature: national drug Standard H19990060), 0.1g × 6 tablets × 1 plate/box.
4. Experimental reagent
56 ° red star Erguotou (manufactured by Beijing red star GmbH); LPS 10mg (sigma corporation, usa); TNF-a ELISA kit (Wuhan Beiyinlie Biotech, inc.); protein quantification kits (white shark Biotechnology Co., ltd.); CD14 rabbit monoclonal antibody (beijing solibao technologies ltd); AQP3 monoclonal antibody (beijing solibao technologies ltd); xylene national chemical group chemical agents ltd; normal rabbit serum: a ServiceBio; hematoxylin staining solution: a ServiceBio; hematoxylin bluing liquid: a ServiceBio; general two-step method kit: china fir gold bridge;
5. laboratory apparatus
A tip micro laboratory sample injection needle of 100 mu l is provided by Shanghai GaoPigeon worker and trade Co., ltd; dewatering machine: DIAPATH Donatello; pathological microtome: shanghai Leica instruments Co., ltd, RM2016; tissue spreading machine: KD-P, kandi instruments and Equipment Co., ltd, jinhua, zhejiang; immunohistochemical pen: servicebio WG1066-1; microscope: nikon E100; an imaging system: nikon DS-U3, japan; 5430R high speed refrigerated centrifuge: ebende China, inc.; centrifuge 5810R low temperature Centrifuge: germany; DW-86-L290-80 ℃ refrigerator: ao De and (5) Koma.
1. The test method comprises the following steps:
1. animal groups mice were bred adaptively for one week, 10 mice were randomly selected as blank groups, and the remaining 20 mice were subjected to damp-heat syndrome model building. After the symptom model is judged to be successful, the model of the operation symptom model is made, and 20 damp-heat mice are randomly divided into a model group and a treatment group.
2. Molding die
2.1 moulding of syndrome model
Blank group: the indoor temperature of an SPF laboratory is 20-25 ℃, the humidity is 50-60%, and the ordinary feed and water are used for feeding for 28 days;
damp-heat model group: the temperature of a damp-heat mode of the artificial climate box is set to be (30 +/-0.15) DEG C, the humidity is 80-90%, the temperature is 8h (10-00-18). Constitutional changes were measured weekly, and symptom model assessment was performed 28 days later.
2.2 pharmaceutical intervention
After 28 days, the stomach was perfused, and the blank group and the model group were perfused with physiological saline of the same volume daily. The treatment group comprises triturating levofloxacin hydrochloride tablets, diluting to 18mg/ml with normal saline, and continuously gavaging for 5 days according to weight 3.6mg (0.2 ml) each time and 1 time/day.
2.3 disease model modeling
1h after last gastric lavage, 40-70 mg/kg pentobarbital sodium is subjected to intraperitoneal injection, skin preparation and disinfection, the medicine is placed into the abdomen from the position which is about 0.5cm slightly below the kidney area behind the back to see white ovarian tissues, the uterus is found out in a proper position, 25 mu l of LPS (2.5 mu g/mu l) is injected into the uterine cavity of a miniature injector (see figure 1), the abdomen is closed according to anatomical levels, the medicine is disinfected, 0.1ml/10g of physiological saline is injected into the abdominal cavity, and the patient is placed into a 28 ℃ artificial climate box to be awakened in a lateral position or a prone position, so that the suffocation death caused by tongue root tenesmus and vomiting is avoided. Blank groups were not processed. After 24h, blood is taken from eyeballs, and the mice are killed after cervical vertebra removal to collect relevant samples and measure indexes.
3. Detecting the index
3.1 uterine pathological examination mouse uterine tissue is fixed by 4% formaldehyde, and pathological tissue changes of each group are observed under a microscope after paraffin embedding, slicing and HE staining.
3.2 immunohistochemical method for detecting the expression of gastric AQP3 and uterine CD14
Dyeing by adopting an SABC method, dewaxing by using dimethylbenzene, replacing the dimethylbenzene by gradient ethanol until water is reached, and washing for 5min by using distilled water. Antigen retrieval was 8min, washing 5min × 3. Incubating with 3% hydrogen peroxide for 25min, and washing for 3 times. 3% BSA blocking for 30min, primary antibody 4 ℃ overnight incubation. Washing for 3 times, incubating the second antibody for 50min, DAB developing, and stopping distilled water. And (4) counterstaining with hematoxylin, dehydrating, transparent, sealing with neutral gum, observing under a microscope, and collecting and analyzing images.
3.3ELISA method for detecting serum TNF-a, IL-10, IL-8 eyeball blood sampling, centrifuging and storing at-80 ℃, and detecting and analyzing the content of mouse serum TNF-a, IL-10, IL-8 according to the steps of ELISA kit.
2. The experimental results are as follows:
1. the mice in the blank group have good mental state, sensitive response, normal drinking water, glossy hair, normal defecation and urination and normal vaginal secretion. The other groups evaluate the damp-heat syndrome model and the disease model: mice are listless and have hypokinesia, slow reaction, dull and lusterless hair, little drinking water amount, dark purple lip, yellow and smelly urine, loose stool, perianal filthy, and vaginal secretion increase, thus conforming to the syndrome model. See fig. 2.
2. Uterine morphology changes in each group of mice: normal group: the uterus has no hyperemia and edema, and the shape is normal; model group uterus: the volume is increased, the lumen is expanded, and the serosal surface is obviously swollen, congested and dark red; treatment groups: the uterus is relieved in size, swelling, congestion and the like. See fig. 3.
3. Mouse uterine HE staining results blank group: the structure of each layer of uterus is clear, the endometrial epithelium is complete, the cell morphology is normal, the number of the uterine glands in the inherent layer is rich, the distribution is uniform, the arrangement of muscle cells in the muscle layer is regular, and no obvious abnormality is seen. Model group: the thickness of the endometrium is uneven, a large amount of epithelial cells of the endometrium are necrotic, and the cell nucleus is deeply dyed, cracked or dissolved and disappears; a small amount of uterine gland epithelial cells in the lamina propria are necrotic, and the cell nucleus is deeply contracted and deeply dyed, cracked or dissolved and disappears; both intimal lamina propria and muscular layer were seen to be infiltrated with a large number of granulocytes (black arrows). Treatment groups: small infiltration of granulocytes was seen in both intimal lamina propria and muscular lamina. See fig. 4.
4. Results of CD14 immunohistochemistry of uterus of mice in each group: and (4) observing under a microscope (the brown membrane is dyed to be strong positive for CD 14), comparing with the normal group, the brown of the model group is darker, which shows that the expression level of CD14 is more, and comparing with the model group, the coloring of the treatment group is obviously lightened, which shows that the expression of CD14 is reduced under the action of levofloxacin hydrochloride. See fig. 5. Through gray level analysis, the CD14 gray level value in the model group is obviously reduced (P < 0.01); the CD14 gray values were elevated in the treatment group compared to the model group (P < 0.01), see fig. 6. The result indicates that the expression of CD14 is positively correlated with the degree of endometritis, which indicates that the model of endometritis disease is successfully modeled. Levofloxacin hydrochloride may control the development of uterine tissue inflammation by reducing the expression of CD14 on endometrial tissue cells. CD14 acts as a receptor for LPS, recognizes and binds LPS, and stimulates monocytes to secrete inflammatory factors.
5. The gastric AQP3 immunohistochemical results of each group of mice are as follows: and through microscopic observation, the color of brown yellow is positive to AQP3, and the color of brown is strong positive. Compared with the normal group, the model group has darker brown color, which indicates that the expression level of gastric AQP3 is more, and compared with the model group, the coloring of the treatment group is reduced, which indicates that the expression of AQP3 can be reduced by levofloxacin hydrochloride. See fig. 7. Through OD value analysis, compared with a model group, the blank group has a remarkably increased AQP3OD value (P < 0.01); the AQP3 gray level was significantly decreased in the treatment group compared to the model group (P < 0.01), see fig. 8. The results show that AQP3 is in positive correlation with the damp-heat model degree, the damp-heat model is successfully molded, and the levofloxacin hydrochloride has the effects of reducing AQP3 and treating damp-heat type endometritis. Aquaporins (AQPs) are a family of membrane proteins that are widely present in various human tissue cells and that pass water through biological membranes to maintain water metabolism balance in the body. The normal expression of AQP3 may be the molecular biological basis for transporting and resolving water dampness and distributing body fluid, and the expression abnormality may be one of the important causes for the formation of damp pathogen, which is closely related to the expression level of aquaporin.
6. ELISA test results of inflammatory factor release of mice in each group: compared with the blank group, the expression of inflammatory factors TNF-a and IL-8 in the model group is obviously increased, and the statistical significance is realized, and P is less than 0.01. Compared with the treatment group, the expression of inflammatory factors TNF-a and IL-8 is obviously reduced in the model group (P < 0.05). The success of the model building of the endometritis model is shown, and the levofloxacin hydrochloride has the obvious effect of inhibiting the endometritis. Compared with the red and white group, the expression of IL-10 in the model group is obviously reduced (P is less than 0.01), and compared with the treatment in the model group, the expression of IL-10 is obviously increased (P is less than 0.01). IL-10 is negatively associated with inflammatory expression and has the effect of inhibiting inflammatory responses. Further proves that the endometritis syndrome model is successfully molded. See fig. 9.
7. Compared with the blank tongue tissue, the model group has the advantages of increased tongue mucosa thickness, increased mucosal layer cornification, darker color dyeing, obvious inflammation, congestion and edema of the inherent layer, and obviously increased nipple density and mitotic phase frequency. The improvement in tongue mucosa thickness and keratosis was not evident in the treated group compared to the model group, but was improved by the alteration of lamina propria inflammation, see figure 10.
8. The research significance of the proinflammatory cytokines TNF-alpha, IL-8 and the anti-inflammatory factor IL-10 is that TNF-alpha is generated by mononuclear macrophage and has wide biological activity. To exert physiological functions of regulating immune response and resisting infection, TNF- α, if present at high concentrations in the body, becomes a serious mediator of inflammation. IL-8 is secreted by neutrophils, T cells, and basophils, is an important chemokine, and plays an important role in inflammatory responses. IL-10 is produced by Th2 cells, has a strong anti-inflammatory effect, and is the main anti-inflammatory factor studied at present. It can directly inhibit the function of macrophage, and also can reduce the excessive damage of inflammation to organism by inhibiting the over-expression of proinflammatory cytokines IL-6, TNF-alpha and the like and controlling the inflammatory waterfall reaction.
In conclusion, the invention adopts a multifactorial pathogenic damp-heat type endometritis mouse model, and lays a foundation for deeply exploring the treatment of damp-heat type endometritis.
Although the present invention has been described in detail with reference to the above embodiments, it is only a part of the embodiments of the present invention, not all of the embodiments, and other embodiments can be obtained without inventive step according to the embodiments, and the embodiments are within the scope of the present invention.
Claims (7)
1. A construction method of a damp-heat type endometritis mouse model comprises the following steps:
1) Feeding the mice with high-fat high-sugar feed in a damp-heat environment, wherein in the feeding process, oil feeding is performed in a single-day mode, and liquor feeding is performed in a double-day mode to obtain damp-heat syndrome model mice;
the feeding period is 25-30 d;
the feeding time in a damp and hot environment is 8-10 h every day;
2) And (3) carrying out endometritis disease model modeling on the damp-heat syndrome model mouse to obtain a damp-heat type endometritis mouse model.
2. The construction method according to claim 1, wherein the temperature of the humid hot environment is 29.85-30.15 ℃; the humidity of the damp and hot environment is 80-90%.
3. The construction method according to claim 1, wherein the high-fat high-sugar feed comprises the following components in percentage by mass: 55% basal feed, 12% palm oil, 18% sucrose, 3% cholesterol, 7% egg yolk powder and 5% protein powder.
4. The construction method according to claim 1, wherein the degree of the white spirit is 50-56 °.
5. The construction method according to claim 4, wherein before the white spirit is fed, the white spirit is diluted by water, and the volume ratio of the water to the white spirit is (1-1.2): 1; the feeding amount of the diluted white spirit is 0.5-0.8 ml/100g of mouse body weight.
6. The method of claim 1, wherein the oil is fed in an amount of 0.5 to 0.8ml/100g mouse body weight.
7. The construction method according to claim 1, wherein the performing of the endometritis disorder model modeling on the damp-heat syndrome model mouse comprises sequentially anesthetizing the damp-heat syndrome model mouse, injecting an LPS aqueous solution into the uterine cavity, and injecting a physiological saline into the abdominal cavity; the concentration of LPS in the LPS aqueous solution is 2-2.5 mug/mul; the injection amount of the LPS aqueous solution is 20-25 mul/piece; the injection amount of the normal saline is 0.08-0.1 ml/10g of mouse body weight.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211113443.2A CN115349498B (en) | 2022-09-14 | 2022-09-14 | Construction method of damp-heat type endometritis mouse model |
DE102023119315.5A DE102023119315A1 (en) | 2022-09-14 | 2023-07-21 | CONSTRUCTION PROCEDURE FOR AN ENDOMETRITIS MOUSE MODEL WITH DAMP-HEAT SYNDROME |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211113443.2A CN115349498B (en) | 2022-09-14 | 2022-09-14 | Construction method of damp-heat type endometritis mouse model |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115349498A true CN115349498A (en) | 2022-11-18 |
CN115349498B CN115349498B (en) | 2023-07-25 |
Family
ID=84007348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211113443.2A Active CN115349498B (en) | 2022-09-14 | 2022-09-14 | Construction method of damp-heat type endometritis mouse model |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115349498B (en) |
DE (1) | DE102023119315A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113142126A (en) * | 2020-12-22 | 2021-07-23 | 安徽医科大学 | Construction method and application of deep injury model of rat endometrium |
KR20220074739A (en) * | 2020-11-27 | 2022-06-03 | 재단법인 국가마우스표현형분석사업단 | In vivo inflammatory signal imaging mouse model, the production method and use thereof |
-
2022
- 2022-09-14 CN CN202211113443.2A patent/CN115349498B/en active Active
-
2023
- 2023-07-21 DE DE102023119315.5A patent/DE102023119315A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220074739A (en) * | 2020-11-27 | 2022-06-03 | 재단법인 국가마우스표현형분석사업단 | In vivo inflammatory signal imaging mouse model, the production method and use thereof |
CN113142126A (en) * | 2020-12-22 | 2021-07-23 | 安徽医科大学 | Construction method and application of deep injury model of rat endometrium |
Non-Patent Citations (5)
Title |
---|
庄梦斐;张婷婷;孙兆贵;曹阳;郁琳;石燕;袁雪菲;: "清热化瘀法对子宫内膜异位症大鼠血管生成和炎症相关因子表达的影响", 中华中医药杂志, no. 05 * |
李伟诗;付开强;吕晓;王雨;曹荣峰;: "LPS诱导小鼠子宫内膜炎模型的建立", 中国兽医杂志, no. 09, pages 96 - 99 * |
杨倩;史万玉;赵驻军;钟秀会;: "小鼠子宫内膜细胞炎症模型的建立", 河北农业大学学报, no. 06 * |
王婷等: "岭南温病湿热证小鼠模型的建立及肠道菌群的研究分析", 中华中医药学刊, vol. 35, no. 6 * |
谢婧;周青;郑锋玲;骆欢欢;: "温病湿热证动物模型中炎症因子与水通道蛋白表达的实验研究", 中华中医药学刊, no. 09 * |
Also Published As
Publication number | Publication date |
---|---|
CN115349498B (en) | 2023-07-25 |
DE102023119315A1 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huang et al. | Perturbation of the lipid metabolism and intestinal inflammation in growing pigs with low birth weight is associated with the alterations of gut microbiota | |
Calefi et al. | The gut-brain axis interactions during heat stress and avian necrotic enteritis | |
Han et al. | FoxO1 regulates TLR4/MyD88/MD2‐NF‐κB inflammatory signalling in mucosal barrier injury of inflammatory bowel disease | |
Luo et al. | Establishment and evaluation of an experimental rat model for high-altitude intestinal barrier injury | |
CN104920299A (en) | Manufacturing method of liver depression type gastric ulcer disease combined animal model | |
Zhao et al. | Candida albicans-induced activation of the TGF-β/Smad pathway and upregulation of IL-6 may contribute to intrauterine adhesion | |
CN109419003A (en) | Breast milk oligosaccharide is preparing the purposes in food or drug | |
CN117305162A (en) | CMU-Pb-L5 and application thereof in preparation of colorectal cancer treatment drugs | |
Fan et al. | Identifying the clinical presentations, progression, and sequela of pelvic inflammatory disease through physiological, histological and ultrastructural evaluation of a rat animal model | |
CN108739668B (en) | Method for establishing animal experiment model by combining spleen and stomach deficiency-cold type gastric ulcer disease and application | |
CN106668034A (en) | Application of L-fucose in medicines and health-care products for treating gastrointestinal lesions | |
CN115337260A (en) | Composite acellular scaffold/hyaluronic acid temperature-sensitive hydrogel and application thereof | |
CN115349498A (en) | Construction method of damp-heat type endometritis mouse model | |
CN119060902A (en) | A strain of Lactobacillus paracasei NCU-04 and its application | |
CN108969513A (en) | A kind of foundation and application of syndrome of stagnation of liver qi and spleen deficiency Animal Model of Ulcerative Colitis | |
CN114767706B (en) | Application of polygonatum odoratum polysaccharide in preparation of medicine for treating asthma | |
CN113693026A (en) | Method for constructing ulcerative colitis animal model | |
CN104095865A (en) | CKD (chronic kidney disease) animal model establishment | |
CN111529519B (en) | Application of atractylodin in preparation of propionibacterium acnes inhibitor | |
CN112972533A (en) | Application of compound agrimony | |
CN112493483A (en) | Use of chlorophyll-rich spinach extract for relieving intestinal inflammatory response and barrier dysfunction | |
CN119015396B (en) | Application of bacteriocin F in the preparation of products for inhibiting Helicobacter pylori | |
CN117643592B (en) | Application of ginsenoside 20 (R) -25-OH-Rg2 in promoting ovarian repair | |
CN118178475B (en) | Application of Lacticaseibacillus paracasei HNU502 in the preparation of products for alleviating side effects of antibiotics | |
CN118217313B (en) | Application of a medical cell CMU-Pb-L5 in the preparation of drugs for preventing and treating allergic asthma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |